Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, BCMA, CAR-T Feb 19 | 2024Could Carvykti Receive a Positive Opinion in Q1 2024? February CHMP AgendaAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Feb 09 | 2024Autolus and BioNTech Enter into Strategic AllianceAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 07 | 2024Yescarta Revenue Decreases while Tecartus Sales Hold; ZUMA-24 Readout Delayed to H2 2024; Anito-cel's Trial in Early Line MM to Initiate in H2 2024; Gilead’s Q4 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, TCR Feb 06 | 2024Thoughts on Regeneron Acquiring 2seventy bio’s Pipeline; How Could Regeneron Leverage its New Cell Therapy Pipeline?Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 05 | 2024Abecma and Breyanzi Revenues Increase; BMS-986353 to be Evaluated in MS; BMS’s Q4 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, TCR Feb 02 | 20242seventy bio to Focus Exclusively on Abecma; Sells Pipeline to Regeneron; Afami-Cel BLA Granted Priority ReviewAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Feb 01 | 2024Kymriah Sales Continue to Decline; No Updates on Cell Therapy Programs; Novartis’s Q4 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jan 31 | 2024Breyanzi Regulatory Applications for R/R FL and R/R MCL Accepted in the US and JapanAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19, Dual/triple agonist Jan 30 | 2024Gracell’s GC012F Receives IND Clearance in Early Line MMAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jan 26 | 2024CHMP Adopts Positive Opinion for Abecma in ≥3L MM; January CHMP HighlightsAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jan 24 | 2024Sales of Carvykti Continue to Grow; FDA and EMA Advisory Committees Will Review Carvykti Applications for Early MM; JNJ Considers Entering in Autoimmune Diseases; JNJ’s Q4 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jan 22 | 2024Obe-cel BLA in R/R B-ALL Accepted Although No Priority Review Was GrantedAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jan 22 | 2024Could Abecma Receive a CHMP Positive Opinion on Friday?; January’s CHMP AgendaAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Jan 12 | 2024JPM 2024 Analysis Day 4: Adaptimmune and CaribouAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, CD19 Jan 12 | 2024JPM 2024 Analysis Days 2 & 3: Imugene, CRISPR Tx, and PrecigenAccess Free BlastFree
Posted in: Allogeneic, CAR-T, CD19 Jan 11 | 2024JPM 2024 Analysis Day 3: AllogeneAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jan 10 | 2024JPM 2024 Analysis Day 2: Legend, AstraZeneca, and BioNTechAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19, Dual/triple agonist Jan 09 | 2024JPM 2024 Analysis Day 1: BMS, Gilead, Novartis, and JNJAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Jan 05 | 2024Poseida Publishes Future Milestones for 2024; Company Considering Entrance in Autoimmune Diseases; Adaptimmune to Pursue Lete-cel Approval By 2026Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Jan 05 | 2024We’re Back! Holiday Recap Ahead of JPM 2024 (Blast 2/2): Risk of Secondary Hematological Malignancies Included in the Black Box of Carvykti’s US Prescribing Information; FDA Approved Yescarta’s Label Update to Incorporate OS Data; Galapagos Initiates Recruitment of GLPG5301 Trial in ≥3L MMAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.